Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions

BMC Cardiovascular Disorders

Eva M Rzucidlo¹  Richard J Powell¹  David H Stone¹  Samantha A Connell¹  Philip P Goodney¹  Daniel B Walsh¹  Karen L Walker¹ 

[1] Section of Vascular Surgery, Dartmouth Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA

关键词: Endovascular;    Thiazolidinediones;    Peripheral arterial disease;    Diabetes;    Adiponectin;   

Others  :  1088409
DOI  :  10.1186/1471-2261-14-184

 received in 2014-09-28, accepted in 2014-12-02,  发布年份 2014

【 摘 要 】

Background

Diabetics are known to have inferior outcomes following peripheral vascular interventions. Thiazolidinediones are oral diabetic agents which improve outcomes following coronary bare metal stenting. No studies have been performed evaluating thiazolidinedione use and outcomes following lower extremity endovascular interventions. We hypothesize that diabetic patients taking thiazolidinediones at the time of primary superficial femoral artery (SFA) stenting have fewer reinterventions.

Methods

A retrospective review was performed to identify diabetic patients undergoing primary SFA stenting. The unit of analysis was the extremity. The primary outcome was freedom from target lesion revascularization stratified by thiazolidinedione use, evaluated by Kaplan Meier curves and a log rank test. A Cox proportional hazards model was constructed to determine variables associated with freedom from target lesion revascularization.

Results

SFA stents were placed in 138 extremities in 128 diabetic patients between August 1, 2001 and July 15, 2012. Twenty-four patients were taking thiazolidinediones at the time of SFA stenting. All patients taking thiazolidinediones had TASC A or B lesions. Twenty-seven extremities in the non-thiazolidinedione group had TASC C or D lesions and were excluded to control for disease severity. Freedom from target lesion revascularization was significantly higher in diabetics taking thiazolidinediones at 2 years, 88.5% vs. 59.4%, P = 0.02, SE < 10%. Cox modeling identified a protective trend for thiazolidinedione use (thiazolidinedione use HR 0.33, 95% CI 0.09-1.13), whereas critical limb ischemia and insulin use were associated with trends for worse freedom from target lesion revascularization.

Conclusions

This pilot, translation study demonstrates that diabetic patients taking thiazolidinediones at the time of primary SFA stenting have decreased reintervention rates at 2 years. These results may be explained by higher adiponectin levels or other anti-inflammatory effects in patients taking thiazolidinedione. National and regional quality improvement registries should consider collecting information regarding specific diabetic regimens and use of PPAR agonists such as cilostazol and fibrates.

【 授权许可】

   
2014 Walker et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hong MS, Beck AW, Nelson PR: Emerging national trends in the management and outcomes of lower extremity peripheral arterial disease. Ann Vasc Surg 2011, 25:44-54.
• [2]Bakken AM, Palchik E, Hart JP, Rhodes JM, Saad WE, Davies MG: Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions. J Vasc Surg 2007, 46:946-958. discussion 958
• [3]Scali ST, Rzucidlo EM, Bjerke AA, Stone DH, Walsh DB, Goodney PP, Chang CK, Powell RJ: Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease. J Vasc Surg 2011, 54:714-721.
• [4]Iida O, Uematsu M, Soga Y, Hirano K, Suzuki K, Yokoi H, Muramatsu T, Inoue N, Nanto S, Nagata S: Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv 2011, 78:611-617.
• [5]Woudstra P, Damman P, Beijk MA, Grundeken MJ, Harskamp RE, Koch KT, Henriques JP, Baan J Jr, Vis MM, Piek JJ, Tijssen JG, de Winter RJ: Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis. Catheter Cardiovasc Interv 2013, 81:26-33.
• [6]Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004, 109:2273-2278.
• [7]Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
• [8]Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, Itoh S, Konno N, Katagiri T: A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006, 29:101-106.
• [9]Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.
• [10]Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792-2798.
• [11]Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K: Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009, 73:343-351.
• [12]Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, Komuro I: Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 2010, 138:157-165.
• [13]Ceriello A: Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008, 24:14-26.
• [14]Hupfeld CJ, Weiss RH: TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol Endocrinol Metab 2001, 281:E207-E216.
• [15]Bruemmer D, Law RE: Thiazolidinedione regulation of smooth muscle cell proliferation. Am J Med 2003, 115(Suppl 8A):87S-92S.
• [16]Fuentes E, Palomo I: Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents. Vasc Pharmacol 2014, 62:162-166.
• [17]Ding M, Carrao AC, Wagner RJ, Xie Y, Jin Y, Rzucidlo EM, Yu J, Li W, Tellides G, Hwa J, Aprahamian TR, Martin KA: Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype. J Mol Cell Cardiol 2012, 52:474-484.
• [18]de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003, 107:2548-2550.
• [19]Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M, Daimon M, Kato T: Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 2001, 50:955-962.
• [20]Igarashi M, Takeda Y, Ishibashi N, Takahashi K, Mori S, Tominaga M, Saito Y: Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm Metab Res 1997, 29:444-449.
• [21]Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487-37491.
• [22]Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51:2968-2974.
• [23]Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
• [24]Moldoveanu E, Mut-Vitcu B, Tanaseanu GR, Marta DS, Manea G, Kosaka T, Vidulescu C, Tanaseanu C: Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: lipoprotein associated phospholipase A2, and myeloperoxidase. Clin Biochem 2008, 41:1429-1433.
• [25]Nishimura M, Hashimoto T, Kobayashi H, Yamazaki S, Okino K, Fujita H, Inoue N, Takahashi H, Ono T: Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol Dial Transplant 2006, 21:1640-1647.
• [26]Kitta Y, Takano H, Nakamura T, Kodama Y, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Mende A, Kobayashi T, Kugiyama K: Low adiponectin levels predict late in-stent restenosis after bare metal stenting in native coronary arteries. Int J Cardiol 2008, 131:78-82.
• [27]Mito T, Miura S, Iwata A, Morii J, Sugihara M, Ike A, Mori K, Kawamura A, Nishikawa H, Zhang B, Saku K: Determination of the cut-off plasma adiponectin level associated with a lower risk of restenosis in patients with stable angina. Coron Artery Dis 2011, 22:451-457.
• [28]Hsieh CJ, Wang PW: Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 2009, 73:948-954.
• [29]Sahebkar A, Watts GF: Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis 2013, 230:110-120.
• [30]Cohen A, Rabbani A, Shah N, Alexander GC: Changes in glitazone use among office-based physicians in the U.S., 2003–2009. Diabetes Care 2010, 33:823-825.
• [31]Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, Christiansen C: Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011, 27:392-401.